UA96308C2 - Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение - Google Patents

Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение

Info

Publication number
UA96308C2
UA96308C2 UAA200904206A UAA200904206A UA96308C2 UA 96308 C2 UA96308 C2 UA 96308C2 UA A200904206 A UAA200904206 A UA A200904206A UA A200904206 A UAA200904206 A UA A200904206A UA 96308 C2 UA96308 C2 UA 96308C2
Authority
UA
Ukraine
Prior art keywords
compounds
receptor antagonist
glucagon receptor
composition
antagonist compounds
Prior art date
Application number
UAA200904206A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джон Е. Стелмак
Эмма Р. Парми
Джеймс Р. Тата
Кит Дж. Росоер
Роналд М. Ким
Эми Р. Биттнер
Цзиан Чан
Кристофер Джозеф Синз
Original Assignee
Мерк Шарп Энд Доме Корп., Сша
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38982644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA96308(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Шарп Энд Доме Корп., Сша filed Critical Мерк Шарп Энд Доме Корп., Сша
Publication of UA96308C2 publication Critical patent/UA96308C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Описан антагонист рецептора глюкагона.Соединения применяются для лечения диабета 2 типа и связанных с ним заболеваний. Также включены фармацевтические композиции и способы лечения., (I)
UAA200904206A 2006-10-03 2007-09-27 Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение UA96308C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84896706P 2006-10-03 2006-10-03

Publications (1)

Publication Number Publication Date
UA96308C2 true UA96308C2 (ru) 2011-10-25

Family

ID=38982644

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904206A UA96308C2 (ru) 2006-10-03 2007-09-27 Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение

Country Status (30)

Country Link
US (3) US20100004158A1 (ru)
EP (1) EP2079688B1 (ru)
JP (1) JP2010505828A (ru)
KR (1) KR20090076907A (ru)
CN (1) CN101535252A (ru)
AR (1) AR063022A1 (ru)
AU (1) AU2007305430B2 (ru)
BR (1) BRPI0717305A2 (ru)
CA (1) CA2664004C (ru)
CL (1) CL2007002841A1 (ru)
CO (1) CO6190512A2 (ru)
CR (1) CR10694A (ru)
DK (1) DK2079688T3 (ru)
EA (1) EA017800B1 (ru)
EC (1) ECSP099225A (ru)
ES (1) ES2390296T3 (ru)
GE (1) GEP20125506B (ru)
IL (1) IL197788A0 (ru)
MA (1) MA31963B1 (ru)
MX (1) MX2009003611A (ru)
NO (1) NO342172B1 (ru)
PE (1) PE20080676A1 (ru)
PL (1) PL2079688T3 (ru)
PT (1) PT2079688E (ru)
SI (1) SI2079688T1 (ru)
TN (1) TN2009000111A1 (ru)
TW (1) TW200821284A (ru)
UA (1) UA96308C2 (ru)
WO (1) WO2008042223A1 (ru)
ZA (1) ZA200901694B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1702919B1 (en) * 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
EP2001472A2 (en) * 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA019752B1 (ru) 2008-03-05 2014-06-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое амидное соединение и его применение для лечения/профилактики диабета
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
ES2714207T3 (es) * 2008-08-13 2019-05-27 Metabasis Therapeutics Inc Antagonistas de glucagón
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2738663A1 (en) * 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
US8445538B2 (en) * 2008-12-19 2013-05-21 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US8697740B2 (en) 2009-01-12 2014-04-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
US20110281795A1 (en) * 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) * 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) * 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
CN103732578B (zh) * 2011-07-22 2015-08-12 辉瑞大药厂 喹啉基胰高血糖素受体调节剂
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
CN107304180B (zh) * 2016-04-22 2022-04-29 浙江海正药业股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN109071420B (zh) * 2016-06-14 2021-06-18 上海昂睿医药技术有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
CN107759522B (zh) * 2016-08-15 2023-04-14 浙江海正药业股份有限公司 羧酸类衍生物、其制备方法及其在医药上的用途
SG11201901355SA (en) 2016-08-30 2019-03-28 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
WO2019040471A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
CA2271963A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
CA2271941A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
SI1042293T1 (sl) 1997-12-19 2008-08-31 Amgen Inc Substituirane piridinske in piridazinske spojine in njihova farmacevtska uporaba
EP1183229B1 (en) 1999-05-17 2005-10-26 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
JP2004501897A (ja) 2000-06-23 2004-01-22 ノボ　ノルディスク　アクティーゼルスカブ グルカゴン拮抗薬／逆作用薬
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002083628A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
BR0212583A (pt) * 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
WO2003048109A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
JP4415216B2 (ja) 2002-02-01 2010-02-17 大日本住友製薬株式会社 ２−フランカルボン酸ヒドラジド化合物及びそれを含有する医薬組成物
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
PT1537078E (pt) * 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
JP2008533200A (ja) * 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
EA200970342A1 (ru) 2009-10-30
JP2010505828A (ja) 2010-02-25
EA017800B1 (ru) 2013-03-29
AU2007305430A1 (en) 2008-04-10
TW200821284A (en) 2008-05-16
AR063022A1 (es) 2008-12-23
MA31963B1 (fr) 2011-01-03
US7968589B2 (en) 2011-06-28
KR20090076907A (ko) 2009-07-13
ECSP099225A (es) 2009-07-31
US20080085926A1 (en) 2008-04-10
CO6190512A2 (es) 2010-08-19
IL197788A0 (en) 2009-12-24
WO2008042223A1 (en) 2008-04-10
US20100144824A1 (en) 2010-06-10
EP2079688B1 (en) 2012-07-25
PT2079688E (pt) 2012-11-22
NO342172B1 (no) 2018-04-09
EP2079688A1 (en) 2009-07-22
CR10694A (es) 2009-05-25
TN2009000111A1 (en) 2010-08-19
GEP20125506B (en) 2012-04-25
CA2664004C (en) 2013-07-23
AU2007305430B2 (en) 2011-07-21
NO20091734L (no) 2009-06-04
CL2007002841A1 (es) 2008-02-08
SI2079688T1 (sl) 2012-12-31
PE20080676A1 (es) 2008-06-12
PL2079688T3 (pl) 2013-01-31
CA2664004A1 (en) 2008-04-10
US7687534B2 (en) 2010-03-30
MX2009003611A (es) 2009-04-22
CN101535252A (zh) 2009-09-16
BRPI0717305A2 (pt) 2014-03-25
ZA200901694B (en) 2010-01-27
US20100004158A1 (en) 2010-01-07
ES2390296T3 (es) 2012-11-08
DK2079688T3 (da) 2012-11-05

Similar Documents

Publication Publication Date Title
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
EP1773330A4 (en) SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
TW200740799A (en) Alpha2C adrenoreceptor agonists
EP1590336A4 (en) SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
EP1942905A4 (en) NICOTINIC ACID RECEPTOR AGONISTS, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF TREATMENT
GEP20074197B (en) 5ht2c receptor modulators
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
EP1874301A4 (en) NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SAME, AND METHODS OF TREATMENT
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL188329A0 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
JO2578B1 (en) Compounds Theophene benzimidazole
GB0524814D0 (en) Compounds
JO2645B1 (en) Vehicles
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола